Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients; and digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions. It also offers PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare organizations including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2026
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2026 | $481M | $29M | $2M | $54M | 0.7% | 14.5% | -103.9% |
| 2025 | $420M | $-26M | $-59M | $8M | -22.1% | 17.8% | -57.2% |
| 2024 | $356M | $-104M | $-137M | $-57M | -54.4% | 26.8% | -22.3% |
| 2023 | $281M | $-149M | $-176M | $-116M | -61.2% | - | - |
| 2022 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2026 |
|---|---|
| Total Revenue | 480.59 |
| Operating Revenue | 480.59 |
| Cost Of Revenue | 154.12 |
| Gross Profit | 326.47 |
| Operating Expense | 333.08 |
| Research And Development | 121.48 |
| Selling General And Administration | 180.15 |
| Total Expenses | 487.20 |
| Operating Income | -6.61 |
| Total Operating Income As Reported | -6.61 |
| EBITDA | 29.47 |
| Normalized EBITDA | 29.97 |
| EBIT | -1.99 |
| Interest Income | 2.17 |
| Interest Expense | 6.95 |
| Net Interest Income | -4.78 |
| Other Non Operating Income Expenses | 2.95 |
| Other Income Expense | 2.45 |
| Interest Income Non Operating | 2.17 |
| Interest Expense Non Operating | 6.95 |
| Net Non Operating Interest Income Expense | -4.78 |
| Pretax Income | -8.94 |
| Tax Provision | -11.25 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | -0.20 |
| Net Income Continuous Operations | 2.31 |
| Net Income From Continuing And Discontinued Operation | 2.31 |
| Net Income From Continuing Operation Net Minority Interest | 2.31 |
| Net Income | 2.31 |
| Net Income Common Stockholders | 2.31 |
| Net Income Including Noncontrolling Interests | 2.31 |
| Normalized Income | 2.61 |
| Diluted NI Availto Com Stockholders | 2.31 |
| Basic Average Shares | 59.74 |
| Diluted Average Shares | 61.49 |
| Reconciled Depreciation | 31.45 |
| Reconciled Cost Of Revenue | 154.12 |
| Total Unusual Items | -0.50 |
| Total Unusual Items Excluding Goodwill | -0.50 |
| Special Income Charges | -0.50 |
| Other Special Charges | 0.50 |
| Depreciation Amortization Depletion Income Statement | 31.45 |
| Depreciation And Amortization In Income Statement | 31.45 |
| General And Administrative Expense | 79.90 |
| Other Gand A | 79.90 |
| Selling And Marketing Expense | 100.24 |
| Otherunder Preferred Stock Dividend | - |
| Amortization | 18.48 |
| Amortization Of Intangibles Income Statement | 18.48 |
| Depreciation Income Statement | 12.97 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Phreesia, Inc.this co. | PHR | $599M | 259.74↑ premium | 1.78 | 0.7% | 21.30 |
| Prime Medicine, Inc. | PRME | $627M | -3.12 | 5.19 | -166.4% | -3.38 |
| Beta Bionics, Inc. | BBNX | $619M | -8.46 | 2.15 | -25.5% | -8.64 |
| Gyre Therapeutics, Inc. | GYRE | $601M | 119.48 | 5.66 | 4.7% | 40.29 |
| Ginkgo Bioworks Holdings, Inc. | DNA | $591M |
| - |
| - |
| - |
| - |
| -1.89 |
| 1.16 |
| -61.5% |
| -3.39 |
| Bioventus Inc. | BVS | $589M | 25.93 | 3.20 | 12.3% | 8.39 |
| Altimmune, Inc. | ALT | $568M | -6.45 | 2.53 | -39.2% | -6.43 |
| Tactile Systems Technology, Inc. | TCMD | $568M | 29.74 | 2.59 | 8.7% | 12.42 |
| MiMedx Group, Inc. | MDXG | $563M | 11.59 | 2.19 | 18.9% | 5.27 |
| Peer Median | - | 4.85 | 2.56 | -10.4% | 0.94 | |